Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma

Hellmann, 2014, Pathological response after neoadjuvant chemotherapy in resectable non–small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint, Lancet Oncol, 15, e42, 10.1016/S1470-2045(13)70334-6 Chaft, 2013, Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non–small-cell lung cancers, J Thorac Oncol, 8, 1084, 10.1097/JTO.0b013e31829923ec Junker, 2001, Grading of tumor regression in non–small cell lung cancer: morphology and prognosis, Chest, 120, 1584, 10.1378/chest.120.5.1584 Junker, 1997, Tumour regression in non–small-cell lung cancer following neoadjuvant therapy, Histological assessment. J Cancer Res Clin Oncol, 123, 469, 10.1007/BF01192200 Pataer, 2012, Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy, J Thorac Oncol, 7, 825, 10.1097/JTO.0b013e318247504a Stefani, 2010, Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients, J Thorac Cardiovasc Surg, 140, 356, 10.1016/j.jtcvs.2010.02.018 Li, 2010, Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non–small cell lung cancer who received neoadjuvant chemotherapy, Lung Cancer, 69, 116, 10.1016/j.lungcan.2009.09.013 Lee, 2010, Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non–small cell lung cancer, J Thorac Oncol, 5, 497, 10.1097/JTO.0b013e3181d2efe7 Scagliotti, 2009, The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies, Oncologist, 14, 253, 10.1634/theoncologist.2008-0232 Strizzi, 2001, Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma, J Pathol, 193, 468, 10.1002/path.824 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non–small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Appel, 2017, Neo-adjuvant chemo-radiation to 60 gray followed by surgery for locally advanced non–small cell lung cancer patients: evaluation of trimodality strategy, Isr Med Assoc J, 19, 614 Betticher, 2003, Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a multicenter phase II trial, J Clin Oncol, 21, 1752, 10.1200/JCO.2003.11.040 Betticher, 2006, Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non–small-cell lung cancer: 5-year follow-up of a phase II study, Br J Cancer, 94, 1099, 10.1038/sj.bjc.6603075 Coroller, 2017, Radiomic-based pathological response prediction from primary tumors and lymph nodes in NSCLC, J Thorac Oncol, 12, 467, 10.1016/j.jtho.2016.11.2226 Liao, 2013, Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non–small-cell lung cancer, Clin Lung Cancer, 14, 418, 10.1016/j.cllc.2012.10.003 Mouillet, 2012, Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non–small-cell lung cancer: combined analysis of two IFCT randomized trials, J Thorac Oncol, 7, 841, 10.1097/JTO.0b013e31824c7d92 Pottgen, 2015, Prognostic model for long-term survival of locally advanced non–small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors, BMC Cancer, 15, 363, 10.1186/s12885-015-1389-4 Remark, 2016, Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients, Oncoimmunology, 5, e1255394, 10.1080/2162402X.2016.1255394 Thomas, 2008, Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non–small-cell lung cancer, Lancet Oncol, 9, 636, 10.1016/S1470-2045(08)70156-6 Yamane, 2010, A novel histopathological evaluation method predicting the outcome of non–small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor, J Thorac Oncol, 5, 49, 10.1097/JTO.0b013e3181c0a1f8 Ofek, 2013, Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis, Modern Pathol, 26, 350, 10.1038/modpathol.2012.171 2015 Amin, 2016 Travis, 2016, The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM Classification of Lung Cancer, J Thorac Oncol, 11, 1204, 10.1016/j.jtho.2016.03.025 Rami-Porta, 2017, Lung cancer — major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 138, 10.3322/caac.21390 Lausen, 1994, Classification and regression trees (CART) used for the exploration of prognostic factors measured on different scales, Contr Stat, 483, 10.1007/978-3-642-57991-2_28 Bland, 1999, Measuring agreement in method comparison studies, Stat Methods Med Res, 8, 135, 10.1177/096228029900800204 Hristov, 2018, Minimally invasive lobectomy is associated with lower noncancer-specific mortality in elderly patients: a propensity score matched competing risks analysis [E-pub ahead of print], Ann Surg Tan, 2018, Competing risks and cancer-specific mortality: why it matters, Oncotarget, 9, 7272, 10.18632/oncotarget.23729 Eguchi, 2017, Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non–small-cell lung cancer: a competing risks analysis, J Clin Oncol, 35, 281, 10.1200/JCO.2016.69.0834 Gray, 1988, A class of K-sample tests for comparing the cumulative incidence of a competing risk, Ann Stat, 16, 1141, 10.1214/aos/1176350951 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 William, 2013, Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non–small-cell lung cancer after neoadjuvant chemotherapy, J Thorac Oncol, 8, 222, 10.1097/JTO.0b013e3182774108 Zheng, 2017, Chemotherapy-induced immunomodulation in non–small-cell lung cancer: a rationale for combination chemoimmunotherapy, Immunotherapy, 9, 913, 10.2217/imt-2017-0052 Butnor Nicholson Blumenthal, 2018, Current status and future perspectives on neoadjuvant therapy in lung cancer, J Thorac Oncol, 13, 1818, 10.1016/j.jtho.2018.09.017